RSS

unresectable hepatocellular carcinoma (uHCC)

Global research and development-based pharmaceutical company, Eisai, has submitted a marketing authorization application to the European Medicines Agency (EMA) for its first-line hepatocellular carcinoma treatment, lenvatinib. more

27 Jul 2017 11:55 News